|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
AU4057300A
(en)
|
1999-03-30 |
2000-10-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinacious compounds
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
MXPA02001417A
(es)
|
1999-08-09 |
2002-08-12 |
Lexigen Pharm Corp |
Complejos multiples de citosina-anticuerpo.
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
KR20030064275A
(ko)
|
2000-06-29 |
2003-07-31 |
메르크 파텐트 게엠베하 |
면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
RU2003129528A
(ru)
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
EP1383785B1
(en)
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
WO2004055056A1
(en)
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
|
ATE447412T1
(de)
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
|
|
ES2367027T3
(es)
*
|
2004-02-27 |
2011-10-27 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
|
|
US20060234205A1
(en)
*
|
2004-03-05 |
2006-10-19 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
WO2009061853A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
WO2012065086A1
(en)
|
2010-11-12 |
2012-05-18 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
AU2015301936B2
(en)
|
2014-08-11 |
2019-03-07 |
Delinia, Inc. |
Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
PT3328894T
(pt)
*
|
2015-08-06 |
2019-02-13 |
Agency Science Tech & Res |
Anticorpos de cadeia comum gama/il2rbeta
|
|
WO2017062832A1
(en)
|
2015-10-08 |
2017-04-13 |
Nektar Therapeutics |
Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JP7422480B2
(ja)
*
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
JP7178906B2
(ja)
*
|
2016-05-19 |
2022-11-28 |
ザ ジェネラル ホスピタル コーポレイション |
ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
EP3475413B1
(en)
*
|
2016-06-22 |
2024-02-14 |
David Klatzmann |
Genetically modified t lymphocytes
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
AU2017378308A1
(en)
*
|
2016-12-13 |
2019-06-20 |
Delinia, Inc. |
Multivalent regulatory T cell modulators
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
WO2018215938A1
(en)
*
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
|
KR20240141853A
(ko)
*
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
KR102777151B1
(ko)
*
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
CN111918665B
(zh)
|
2018-03-28 |
2024-11-26 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
MX2021000801A
(es)
*
|
2018-07-24 |
2021-04-12 |
BioNTech SE |
Agonistas de il2.
|
|
US12403181B2
(en)
|
2018-08-13 |
2025-09-02 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
US11492384B2
(en)
*
|
2018-09-17 |
2022-11-08 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
EP3854805A4
(en)
|
2018-09-21 |
2022-08-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
NOVEL INTERLEUKIN 2 AND ITS USE
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
KR20210107714A
(ko)
|
2018-12-21 |
2021-09-01 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
인간 인터류킨-2 변이체 또는 이의 유도체
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
PH12022550326A1
(en)
*
|
2019-08-13 |
2023-03-13 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
BR112022011414A2
(pt)
|
2019-12-12 |
2022-08-30 |
Iltoo Pharma |
Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
|
|
IL293471A
(en)
|
2019-12-17 |
2022-08-01 |
Amgen Inc |
Dual interleukin-2 / tnf receptor agonist for use in medicine
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
WO2021146436A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
CA3166009A1
(en)
*
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 muteins
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
JP2023518434A
(ja)
|
2020-03-19 |
2023-05-01 |
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド |
インターロイキン２変異体およびその使用
|
|
CN118271419A
(zh)
|
2020-03-31 |
2024-07-02 |
韩美药品株式会社 |
新型免疫刺激il-2类似物
|
|
KR20230019889A
(ko)
|
2020-06-03 |
2023-02-09 |
아센디스 파마 온콜로지 디비전 에이/에스 |
Il-2 서열 및 이의 용도
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
JP2023548311A
(ja)
|
2020-10-29 |
2023-11-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
疾患の治療のための融合タンパク質
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
EP4406965A4
(en)
|
2021-09-22 |
2025-12-17 |
Fortvita Biologics Singapore Pte Ltd |
INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH
|
|
CN118414160A
(zh)
|
2021-10-06 |
2024-07-30 |
艾尔图制药公司 |
对发炎组织具有靶向特异性的白介素2嵌合构建体
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
US20240076343A1
(en)
*
|
2022-06-16 |
2024-03-07 |
Cephalon Llc |
Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
|
|
EP4587043A1
(en)
|
2022-09-12 |
2025-07-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Interleukin-2 for use in treating autism spectrum disorder
|
|
FR3140287B1
(fr)
|
2022-10-03 |
2025-11-21 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|
|
AU2023382265A1
(en)
|
2022-11-18 |
2025-10-09 |
Nanjing Novoacine Biotechnology Co., Ltd. |
Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof
|